Back to Journals Drug Design, Development and Therapy Volume 19 The Role of Radiosensitizing Drugs in Osteosarcoma Treatment: Mechanisms and Clinical Perspectives Authors Zhang Y, Xie Y, Wang Y, Huang P, Lu Y Received 16 December 2024 Accepted for publication 9 March 2025 Published 14 March 2025 Volume 2025:19 Pages 19271942 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Dr Muzammal Hussain Yilei Zhang, * Yuhuan Xie, * Yiwen Wang, * Panpan Huang, Yao Lu School of Basic Medicine, Gannan Medical University, Ganzhou, Jiangxi, 341000, Peoples Republic of China *These authors contributed equally to this work Correspondence: Yao Lu
Bone Strength and Integrity Bone health depends on both vitamin D and B12
These water-soluble injections bypass digestive challenges, ensuring full absorption into the bloodstream
Wooten and her team
Oral peptide delivery Peptides and weight loss BPC-157 benefits & safety TB-500 5mg peptide Thymogen peptide
Key Characteristics of Cagrilintide 5mg + Semaglutide 5mg Dual-Pathway Peptide Combination : Combines amylin-pathway activation (cagrilintide) with GLP-1 receptor activation (semaglutide) to study two key gutbrain hormone systems involved in satiety and metabolic regulation